SV2008002466A - Oblea que contiene hormonas esteroides ref. p-sv-79.953/gh - Google Patents

Oblea que contiene hormonas esteroides ref. p-sv-79.953/gh

Info

Publication number
SV2008002466A
SV2008002466A SV2006002466A SV2006002466A SV2008002466A SV 2008002466 A SV2008002466 A SV 2008002466A SV 2006002466 A SV2006002466 A SV 2006002466A SV 2006002466 A SV2006002466 A SV 2006002466A SV 2008002466 A SV2008002466 A SV 2008002466A
Authority
SV
El Salvador
Prior art keywords
steroid hormones
oblea
ref
blood
application system
Prior art date
Application number
SV2006002466A
Other languages
English (en)
Spanish (es)
Inventor
Markus Krume
Sascha General
Albert Radlmaier
Michael Dittgen
Keith Jensen
Original Assignee
Lts Lohmann Therapie Systeme Ag
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36998911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2008002466(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lts Lohmann Therapie Systeme Ag, Schering Ag filed Critical Lts Lohmann Therapie Systeme Ag
Publication of SV2008002466A publication Critical patent/SV2008002466A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SV2006002466A 2005-03-31 2006-03-27 Oblea que contiene hormonas esteroides ref. p-sv-79.953/gh SV2008002466A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005015128A DE102005015128B4 (de) 2005-03-31 2005-03-31 Wafer enthaltend Steroidhormone

Publications (1)

Publication Number Publication Date
SV2008002466A true SV2008002466A (es) 2008-02-08

Family

ID=36998911

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2006002466A SV2008002466A (es) 2005-03-31 2006-03-27 Oblea que contiene hormonas esteroides ref. p-sv-79.953/gh

Country Status (26)

Country Link
US (2) US9763960B2 (enExample)
EP (1) EP1863444B1 (enExample)
JP (2) JP5843416B2 (enExample)
KR (2) KR20140063740A (enExample)
CN (2) CN104983669B (enExample)
AR (1) AR054245A1 (enExample)
AU (1) AU2006228820B2 (enExample)
BR (1) BRPI0609601A2 (enExample)
CA (1) CA2598892C (enExample)
CR (1) CR9468A (enExample)
DE (1) DE102005015128B4 (enExample)
DO (1) DOP2006000070A (enExample)
EA (1) EA014183B1 (enExample)
GT (1) GT200600126A (enExample)
IL (1) IL186081A0 (enExample)
MX (1) MX2007012081A (enExample)
NO (1) NO20075404L (enExample)
NZ (1) NZ592882A (enExample)
PE (1) PE20061194A1 (enExample)
SG (1) SG179459A1 (enExample)
SV (1) SV2008002466A (enExample)
TW (1) TWI393576B (enExample)
UA (1) UA92011C2 (enExample)
UY (1) UY29441A1 (enExample)
WO (1) WO2006102990A2 (enExample)
ZA (1) ZA200706116B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US8241664B2 (en) 2005-04-15 2012-08-14 Clarus Therapeutics, Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
DE102006027796A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Estrogen-Gestagen-Kombinationen
NZ586666A (en) * 2008-02-13 2012-04-27 Bayer Schering Pharma Ag Estradiol-containing drug delivery system
KR20100117603A (ko) * 2008-02-13 2010-11-03 바이엘 쉐링 파마 악티엔게젤샤프트 안정화 효과를 갖는 약물 전달 시스템
TW201008569A (en) * 2008-08-08 2010-03-01 Bayer Schering Pharma Ag Progestin-containing drug delivery system
CA2744127A1 (en) * 2008-11-21 2010-05-27 Bayer Schering Pharma Aktiengesellschaft Drug delivery system
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
EP2493457B1 (en) 2009-10-30 2017-08-09 IX Biopharma Ltd Fast dissolving solid dosage form
US10806703B2 (en) * 2012-01-20 2020-10-20 Lts Lohmann Therapie-System Ag Transmucosal administration system for a pharmaceutical drug
AU2012385956B2 (en) 2012-07-23 2017-03-30 Crayola, Llc Dissolvable films and methods of using the same
DE102017112527B4 (de) * 2017-06-07 2019-01-03 Lts Lohmann Therapie-Systeme Ag Schnell zerfallende Schaumwafer mit hohem Flächengewicht
MX2020008147A (es) * 2018-02-02 2020-10-28 Acerus Biopharma Inc Metodos de terapia de testosterona.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB981372A (en) * 1960-05-04 1965-01-27 Pfizer Ltd Pharmaceutical formulations for oral administration to animals
US4136162A (en) 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
DE69312487T2 (de) * 1992-05-18 1997-11-27 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
DE19847252B4 (de) * 1998-10-02 2004-02-12 Jenapharm Gmbh & Co. Kg Bukkal applizierbare bioadhäsive Systeme mit zeitlich gesteuerter Wirkstofffreisetzung enthaltend Testosteronester und fakultativ zusätzlich Testosteron
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20030092658A1 (en) * 2001-02-02 2003-05-15 Meyers Rachel E. Novel human enzyme family members and uses thereof
AU2001273231A1 (en) * 2000-07-06 2002-01-21 Delsys Pharmaceutical Corporation Method for formulating healthcare products with enhanced stability
GB0100760D0 (en) * 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
FR2832311B1 (fr) * 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
JO2492B1 (en) * 2003-04-28 2009-10-05 شيرينج ايه جي A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
JP2007500729A (ja) * 2003-07-31 2007-01-18 アイバックス コーポレイション 雄性及び雌性の性機能障害の治療方法
PL1670433T3 (pl) * 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze

Also Published As

Publication number Publication date
JP2013155190A (ja) 2013-08-15
EA200702102A1 (ru) 2008-04-28
WO2006102990A2 (de) 2006-10-05
JP5843416B2 (ja) 2016-01-13
TW200714299A (en) 2007-04-16
US9763960B2 (en) 2017-09-19
AU2006228820B2 (en) 2011-08-25
ZA200706116B (en) 2008-11-26
KR20140063740A (ko) 2014-05-27
EP1863444A2 (de) 2007-12-12
JP2008534533A (ja) 2008-08-28
US20060222708A1 (en) 2006-10-05
CN104983669A (zh) 2015-10-21
BRPI0609601A2 (pt) 2010-04-20
NZ592882A (en) 2012-12-21
KR20080002798A (ko) 2008-01-04
SG179459A1 (en) 2012-04-27
TWI393576B (zh) 2013-04-21
CN101132766A (zh) 2008-02-27
DE102005015128B4 (de) 2008-12-11
CN104983669B (zh) 2018-05-18
EP1863444B1 (de) 2015-12-09
PE20061194A1 (es) 2006-11-23
US20170348321A1 (en) 2017-12-07
GT200600126A (es) 2007-03-14
DE102005015128A1 (de) 2006-10-05
NO20075404L (no) 2007-12-20
AU2006228820A1 (en) 2006-10-05
MX2007012081A (es) 2007-11-21
WO2006102990A3 (de) 2007-03-22
IL186081A0 (en) 2008-01-20
KR101428625B1 (ko) 2014-08-13
UA92011C2 (ru) 2010-09-27
DOP2006000070A (es) 2007-08-15
AR054245A1 (es) 2007-06-13
EA014183B1 (ru) 2010-10-29
CR9468A (es) 2008-01-21
CA2598892C (en) 2014-10-14
UY29441A1 (es) 2006-10-31
CA2598892A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
SV2008002466A (es) Oblea que contiene hormonas esteroides ref. p-sv-79.953/gh
AR059174A1 (es) Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas)
AR033418A1 (es) Preparado farmaceutico mucoadhesivo desintegrable para la administracion de sustancia activa en medicina veterinaria y humana
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
BRPI0416370A (pt) sistema de distribuição de liberação controlada para aplicações nasais
GT201000182A (es) Regimen de dosificacion asociado con ésteres de paliperidona inyectables de acción prolongada
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
EA201190127A1 (ru) Фармацевтические составы нитазоксанида с контролируемым высвобождением
CR20120019A (es) Composicion de insulina de accion prolongada
PE20030519A1 (es) Forma de dosificacion, dispositivo y metodos de tratamiento
PE20211492A1 (es) Composiciones estables de semaglutida y usos de las mismas
PE20191149A1 (es) Uso farmaceutico de una composicion que contiene pirfenidona de liberacion prolongada (pfd-lp) para la reversion y tratamiento de la esteatohepatitis humana (nafld/nash)
ATE507818T1 (de) Orale verabreichung eines calcitonins
PE20081881A1 (es) Agentes terapeuticos para canceres resistentes a agentes quimioterapicos que incluyen como ingrediente activo un anticuerpo que reconoce hla de clase i y sus usos
ECSP099611A (es) Composiciones farmaceuticas que comprenden un agente calcilitico
AR075082A1 (es) Utilizacion de vitamina e o sus derivados para el control de artropodos
CL2012003119A1 (es) Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre.
AR056500A1 (es) Metodo para preparar una composicion medica
UY31097A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsionante
UY32354A (es) Composición de micropartículas biocompatibles de ácido algínico para la liberación
SV2007002235A (es) Nuevos derivados de pirimidina y su uso ref. bhc041311-sv
AR044675A1 (es) Metodo para el tratamiento de la esquizofrenia en un paciente con sobrepeso
AR080541A1 (es) Tratamiento para la endometriosis
CU20070219A7 (es) Oblea que contiene hormonas esteroides
AR067351A1 (es) Combinacion de picotamida con nafronil

Legal Events

Date Code Title Description
FG Grant
FD Lapse